RUBIUS THERAPEUTICS INC's ticker is RUBY and the CUSIP is 78116T103. A total of 74 filers reported holding RUBIUS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $293,417 | -60.3% | 1,676,669 | -1.7% | 0.00% | – |
| Q3 2022 | $740,000 | -55.1% | 1,705,288 | -12.0% | 0.00% | – |
| Q2 2022 | $1,648,000 | -87.2% | 1,937,193 | -16.9% | 0.00% | – |
| Q1 2022 | $12,843,000 | -59.1% | 2,330,725 | -28.2% | 0.00% | -100.0% |
| Q4 2021 | $31,427,000 | -45.7% | 3,246,641 | +0.4% | 0.00% | 0.0% |
| Q3 2021 | $57,843,000 | -26.9% | 3,235,007 | -0.2% | 0.00% | -50.0% |
| Q2 2021 | $79,148,000 | -3.6% | 3,242,403 | +4.6% | 0.00% | 0.0% |
| Q1 2021 | $82,113,000 | +349.2% | 3,098,602 | +28.6% | 0.00% | +100.0% |
| Q4 2020 | $18,281,000 | +54.0% | 2,408,755 | +1.7% | 0.00% | – |
| Q3 2020 | $11,869,000 | -37.2% | 2,369,274 | -25.0% | 0.00% | -100.0% |
| Q2 2020 | $18,892,000 | +41.3% | 3,159,130 | +5.1% | 0.00% | 0.0% |
| Q1 2020 | $13,370,000 | -52.9% | 3,004,433 | +0.5% | 0.00% | 0.0% |
| Q4 2019 | $28,392,000 | +24.6% | 2,988,657 | +2.9% | 0.00% | 0.0% |
| Q3 2019 | $22,795,000 | -46.8% | 2,903,831 | +6.5% | 0.00% | -50.0% |
| Q2 2019 | $42,876,000 | +12.2% | 2,725,717 | +29.1% | 0.00% | +100.0% |
| Q1 2019 | $38,209,000 | +139.0% | 2,110,958 | +112.3% | 0.00% | 0.0% |
| Q4 2018 | $15,987,000 | -31.5% | 994,249 | +2.3% | 0.00% | 0.0% |
| Q3 2018 | $23,329,000 | – | 972,032 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |